GlassScriptPhysician profile
Natalie Ann Spicer
NPI 1174197065
$2,807.28
in general payments reported to CMS, 2019-2025
10 companies · $296 in 2025
The $296 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,511 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,471 · Travel and Lodging: $1,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,471.21 |
| Travel and Lodging | $1,336.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,999.99 | 2024 | Ortholoc 3di, Anchorage, Actishield |
| Integra Lifesciences Corporation | $397.60 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Medtronic, INC. | $148.57 | 2025 | Hawkone |
| Globus Medical, INC. | $105.01 | 2025 | Senza |
| Organogenesis INC. | $51.71 | 2024 | Apligraf |
| Convatec INC. | $30.06 | 2024 | |
| Smith+Nephew, INC. | $23.04 | 2025 | Grafix Pl |
| Mimedx Group, INC. | $19.61 | 2025 | |
| Nevro Corp. | $17.66 | 2024 | Senza |
| Paratek Pharmaceuticals, INC. | $14.03 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Spicer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.